NCT00408421已完成3 期
Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 231
- 试验地点
- 1
- 主要终点
- Weekly Change From Baseline in the 24-Hour Average Pain Rating Using an 11-Point Numerical Likert Scale Patient Diary
研究概览
简要总结
The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female outpatients with osteoarthritis knee pain.
排除标准
- •Cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.
- •Acute liver injury (such as hepatitis) or severe cirrhosis.
- •Previous exposure to duloxetine.
- •Body Mass Index (BMI) over
- •Major depressive disorder.
- •Daily use of narcotics.
研究组 & 干预措施
A
Experimental
duloxetine 30 mg, daily (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 6 weeks then duloxetine 60 mg or 120 mg QD, PO for 6 weeks
干预措施: Duloxetine (Drug)
B
Placebo Comparator
placebo daily (QD), by mouth (PO) for 13 weeks
干预措施: placebo (Drug)
结局指标
主要结局
Weekly Change From Baseline in the 24-Hour Average Pain Rating Using an 11-Point Numerical Likert Scale Patient Diary
时间窗: Over 13 Weeks
This is an ordinal scale assessing the 24-hour average pain with scores from 0 (no pain) to 10 (worst possible pain).
次要结局
- Patient Global Impression of Improvement at 13 Week Endpoint(13 Weeks)
- Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Pain Subscale(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Stiffness Subscale(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Physical Function Subscale(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Total Score(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Weekly Mean of the 24-Hour Worst Pain Score(Baseline and 13 Weeks)
- Weekly Change From Baseline in the 24-Hour Worst Pain Score(Over 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Weekly Mean of 24-Hour Average Pain in the Re-Randomized Treatment Phase(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Clinical Global Impression of Severity(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) - Worst Pain Score(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Least Pain Score(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Average Pain Score(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Pain Right Now Score(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - General Activity(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Mood(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Walking Ability(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Normal Work(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Relations With Other People(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Sleep(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Enjoyment of Life(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Average Interference(Baseline and 13 Weeks)
- Response to Treatment - The Number of Participants With a >= 30% Reduction of Weekly Mean in 24-Hour Average Pain Severity Ratings(Over 13 Weeks)
- Response to Treatment - The Number of Participants With a >=30% Reduction of Weekly Mean in 24-Hour Average Pain Severity Ratings in the Re-Randomized Treatment Phase(Over 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Medical Outcomes Study Short Form-36 (SF-36) - Mental Health Component Summary(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Medical Outcomes Study Short Form-36 (SF-36) - Physical Component Summary(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Euro-Quality of Life - 5 Dimensions (EQ-5D): US Based Index Score(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Beck Depression Inventory-II - Total Score(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale(Baseline and 13 Weeks)
- Statistically Significant Change From Baseline to 13 Week Endpoint in Laboratory Data - Chemistry Analytes: Alkaline Phosphatase(Baseline and 13 Weeks)
- Statistically Significant Change From Baseline to 13 Week Endpoint in Laboratory Data - Chemistry Analytes: Uric Acid(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Vital Signs - Pulse Rate(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Vital Signs - Blood Pressure (BP) Diastolic(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Vital Signs - Blood Pressure (BP) Systolic(Baseline and 13 Weeks)
- Change From Baseline to 13 Week Endpoint in Vital Signs - Weight(Baseline and 13 Weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee PainOsteoarthritis Knee PainNCT00433290Eli Lilly and Company256
已完成
3 期
Duloxetine Versus Placebo for FibromyalgiaFibromyalgiaNCT00489073Eli Lilly and Company345
已完成
3 期
Duloxetine Versus Placebo in the Treatment of FMSFibromyalgiaNCT00233025Eli Lilly and Company320
已完成
3 期
A Study of Duloxetine in Patients With Osteoarthritis Knee PainOsteoarthritis Knee PainNCT00945945Eli Lilly and Company424
已完成
3 期
Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia SyndromeFibromyalgiaNCT00190866Eli Lilly and Company210